Skip to main content
64°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Relief Therapeutics Hldg Ag
(OP:
RLFTF
)
1.350
UNCHANGED
Streaming Delayed Price
Updated: 3:03 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Relief Therapeutics Hldg Ag
< Previous
1
2
3
4
5
6
Next >
Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
February 01, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / February 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
January 31, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
January 27, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 27, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Death
Exposures
COVID-19
Death
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
January 24, 2022
Notice of Allowance of Patent Application for a Non-Steroidal Anti-Inflammatory, Diclofenac Potassium, Strengthens Proprietary Position in U.S. until 2039 GENEVA, SWITZERLAND / ACCESSWIRE / January 24,...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
January 19, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 19, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
January 14, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Relief Comments on Lawsuit Filed Against It by NeuroRx
January 12, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 12, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
January 06, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Relief Therapeutics to Participate in Virtual Investor Conferences in January
January 05, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 5, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
January 04, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
January 03, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 3, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
December 30, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 30, 2021 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
December 28, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 28, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
December 16, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed a Registration Statement on Form 20-F...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
December 15, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQBRLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
December 10, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 10, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Announces Executive Changes
November 30, 2021
- Nermeen Varawalla, MD, PhD, MBA appointed Chief Medical Officer, replacing Gilles Della Corte, MD - Jeremy Meinen promoted to Chief Accounting Officer - Marco Marotta promoted to Chief Business...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
November 29, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 29, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
November 24, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has signed a collaboration agreement (the "...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
COVID-19
Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
November 24, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Therapeutics Launches Level 1 ADR Program in the United States
November 18, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 18, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), announced today that its Form F-6 registration statement has become effective,...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information
November 12, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 12, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100(TM) (Aviptadil)
November 11, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development
November 09, 2021
- Anthony M. Kim Appointed Senior Vice President and Head of U.S. Commercial Operations - Seasoned Biotech Executive Brings Vast U.S. Commercial Launch Experience to Relief - European and United...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
November 05, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 5, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Takes First Step to Create an ADR Program in the United States by Filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
November 03, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), announced today that it has taken the first steps to establish a Level 1 American...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
November 03, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients
October 27, 2021
Results Confirm the Safety and Tolerability of Sentinox and Suggest It Could Be Effective in Reducing Time to Negativization in SARS-CoV-2 Infected Patients GENEVA, SWITZERLAND / ACCESSWIRE / October...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers
October 20, 2021
A Prospective Series on Wound Bed Preparation with Nexodyn(R) AOS and Standard of Care and a 32-Week Follow-Up Study Published in the Peer Reviewed Journal of Wound Care GENEVA, SWITZERLAND /...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
October 15, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / October 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.